drugset / Trial / NCT00902928

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

NCT00902928

Phase 2/3 Completed 1992 enrolled Astellas Pharma Europe B.V.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the efficacy and safety of various doses of YM150 (the experimental drug) compared to enoxaparin in the prevention of venous thromboembolism in patients that are undergoing elective hip replacement surgery.

Timeline

Start
2009-04
Primary completion
2010-06
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject darexaban Small molecule 15 mg Oral
Subject darexaban Small molecule 30 mg Oral
Subject darexaban Small molecule 60 mg Oral